Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Boehlen – page 12

1 042 clinical trials in Boehlen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Boehlen at a glance
1 042
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 042 trials in Boehlen

Open in trial search

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Astellas Pharma Global Development Inc.

Epcoritamab for Adults with Relapsed or Refractory Marginal Zone Lymphoma: A Phase II Open‑Label Study

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaetsklinikum Ulm AöR

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Colitis ulcerative+2

Recruiting

Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY4395089
  • Sponsor:Eli Lilly & Co.

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Verastem Inc.

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:GWT-Tud GmbH

Asthma

Recruiting

Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Indacaterol Acetate
  • Sponsor:Novartis Pharma AG

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Boehlen

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on Irritable Bowel Syndrome (IBS), specifically targeting the diarrhea-predominant form. The research evaluates an innovative bacterial treatment approach using E. coli DSM 17252 to improve digestive health outcomes.

  • Symptom Management
  • Microbiome-Based Therapy
  • Gastrointestinal Disorders

This trial aims to advance treatment options for patients dealing with chronic digestive symptoms.

02 Immunology Studies

Groundbreaking research into IgG4-Related Disease, evaluating the effectiveness of obexelimab administered subcutaneously. The study focuses on preventing disease flares following glucocorticoid therapy.

  • Autoimmune Conditions
  • Disease Management
  • Novel Therapeutic Approaches

This research represents a significant step forward in developing targeted treatments for rare immunological disorders.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.